Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women

Because of its unique features, the contraceptive effectiveness and tolerance during breast-feeding of 16-methylene-17α-acetoxy-19-nor-4-pregnene-3,20-dione (elcometrine), delivered within a single subdermal capsule of medical grade polydimethylsiloxane, was investigated. Unlike other progestational...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 1999-02, Vol.59 (2), p.115-122
Main Authors: Coutinho, Elsimar M, Athayde, Celia, Dantas, Claudia, Hirsch, Cristina, Barbosa, Ione
Format: Article
Language:English
Subjects:
Adult
Amenorrhea
Biological and medical sciences
Birth control
Body Constitution
Body Weight
Breast Feeding
Child Development
contraception
Contraceptive Agents, Female - administration & dosage
Contraceptive Agents, Female - pharmacokinetics
Drug Implants
elcometrine
Female
Gynecology. Andrology. Obstetrics
Hormonal contraception
Humans
Infant
infant development
Intrauterine Devices, Copper
lactation
Medical sciences
Menstruation
Milk, Human - chemistry
Norprogesterones - administration & dosage
Norprogesterones - pharmacokinetics
Population
Postpartum Period
ST-1435
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Because of its unique features, the contraceptive effectiveness and tolerance during breast-feeding of 16-methylene-17α-acetoxy-19-nor-4-pregnene-3,20-dione (elcometrine), delivered within a single subdermal capsule of medical grade polydimethylsiloxane, was investigated. Unlike other progestational steroids, elcometrine has no affinity for androgen and estrogen receptors and is inactive by the oral route. A total of 66 breast-feeding women receiving elcometrine by the subdermal route were enrolled in the study, and 69 women who elected to use Copper-T380 intrauterine devices (IUD) served as control subjects. The women and their infants were observed until the end of the first postpartum year. There were no significant differences in growth and development measurements among the infants in the elcometrine and control groups. The percentage of infants continuing to breast-feed at 3 and 6 months was significantly higher in the elcometrine group. There were no significant differences between the concentration of elcometrine in the mother’s blood and milk. At 75 days, blood levels of elcometrine in the infants were near the undetectable and were significantly lower than the levels in maternal blood or milk (p
ISSN:0010-7824
1879-0518
DOI:10.1016/S0010-7824(99)00004-9